

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
PH0249

10 FEB 2004  
TBA

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT Frank Brady, et.al.

FILING DATE  
Herewith

GROUP  
To Be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	94/27591	12/1994	WO				
	95/14461	06/1995	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	J. Owens et.al.: Nuclear Medicine & Biology, vol. 27, no. 6, 2000, pages 557-564
	A.R. Gibbs, et.al: Journal of Labelled Compounds and Radiopharmaceuticals, vol. 45, no. 5, April 2002 pages 395-400
	A.A. Wilson, et.al.: J. Med. Chem. Vol. 34, no.6, 1991, pages 1867-1870
	CAPLUS Abstract Accession No. 2002:370623 & Journal of Labelled Compounds & Radiopharmaceuticals Vol. 45, No. 5, 2002, Andrew R Gibbs, et.al, "Synthesis of N-(2-chloro-5-methylthiophenyl)-N'-(3-methylthiophenyl)-N'-[3H3]methylguanidine, {[3H3]CNS-5161}" , pages 395-400 [see abstract]
	CAPLUS Abstract Accession No. 2002:274772 & British Journal of Clinical Pharmacology Vol. 53, No. 3, 2002, MR Walters, et.al, "Early clinical experience with the novel NMDA receptor antagonist CNS 5161", pages 305-311 (see abstract)
	CAPLUS Abstract Accession No. 2001: 177402 & Biorganic & Medicinal Chemistry Letters Vol. 11, No. 4, 2001, S Padmanabhan et.al., "Identification and characterization of a potential ischemia-selective N-methyl-d-aspartate (NMDA) receptor ion-channel blocker, CNS 5788, pages 501-504 (see abstract)
	CAPLUS Abstract Accession No. 1998:35396 & Journal of Medicinal Chemistry Vol. 40, No. 26, 1997, Lain-Yen Hu, et.al, "Synthesis and pharmacological evaluation of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methylguanidines as N-methyl-D-aspartate receptor ion-channel blockers", pages 4281-4289 (see abstract)
	International Search Report for PCT/GB03/03078 DATED Oct. 8, 2003

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

DT Dec'd PCT/PTO 18 JAN 2005 of 2

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
PH0249107522204  
TBAINFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT Frank Brady, et.al.

FILING DATE  
HerewithGROUP  
To Be Assigned

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	British Search Report for GB0216621.3 dated Dec. 20, 2002
	Joannes TM Linders, Current Opinion in CPNS Investigation Drugs 1999, pages 167-170
	Paula M. Bokesch, Anesthesiology, pages 202-208
	A. Bigeon, et.al., Development of CNS5161 for NMDA Receptor Imaging, J. Nucl. Med. 43 (2002) No. 1447 page 360P

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.